ClinicalTrials.gg
RecruitingNCT07951528Updated Nov 20, 2026

Association Between Childhood Obesity and Myopia: A Prospective Cohort Study

An observational study in Obesity and Myopia, sponsored by Southeast University, China. Recruiting at 1 site in China. Open to participants aged 6 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Southeast University, China · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 603 studies in Obesity with a site in China — 223 open to participants now, 284 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
44th of 99
600 · median 320
Started
2025
with 114 others
Observational
99 of 603
37 open now
Primary completion
2027-07
later than 180 of 282 live
Registered
602nd of 603
by date

Among the 603 studies in Obesity with a site in China, this one is the 44th largest by planned enrollment of the 99 observational ones that give a count, is one of 115 that started in 2025, is one of 99 observational ones, reaches primary completion later than 180 of the 282 other live ones, and was the 602nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,059 are open to participants now.

Browse Obesity studies →

Open to participants now

223 of the 603 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

218 more — sign in →

All 223 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,350 Obesity studies recruiting now, 382 (28%) set no upper age limit and 864 (64%) stop at 75 or younger; 168 take children under 18; 490 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This prospective observational cohort study will examine the association between obesity and myopia in children and adolescents. Approximately 600 participants aged 6 to 18 years will be enrolled at the Fourth Affiliated Hospital of Nanjing Medical University, including 300 participants with obesity and 300 participants with a body mass index within the normal range.

Participants will not be assigned to any study intervention. The study will collect information from body measurements, body composition assessments, eye examinations, lifestyle questionnaires, follow-up assessments, and existing clinical records. The investigators will evaluate whether obesity-related measures, including body mass index, body mass index z-score, body fat percentage, and visceral fat, are associated with myopia, axial length, refractive status, and changes in these outcomes over time. Lifestyle factors such as outdoor activity, near work, screen use, sleep, and diet will also be considered.

Read the detailed description

This is a single-center, prospective, observational cohort study involving children and adolescents aged 6 to 18 years who attend the pediatric outpatient clinic of the Fourth Affiliated Hospital of Nanjing Medical University. Approximately 600 participants will be enrolled, including 300 participants with obesity and 300 participants with a body mass index within the normal range. Obesity will be defined according to the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018).

No randomization, masking, or study-related clinical intervention will be performed. At baseline, the study will collect anthropometric measurements, body composition data, ophthalmic examination results, and lifestyle questionnaire data. Planned follow-up assessments will be used to evaluate changes in refractive status, axial length, scleral thickness, and myopia progression.

The principal study outcomes include myopia status and changes in axial length, spherical equivalent refraction, scleral thickness, and myopia progression. The study will examine associations between these outcomes and obesity-related measures, including body mass index, body mass index z-score, body fat percentage, and visceral fat.

Information on age, sex, parental history of myopia, birth history, medical history, medication use, outdoor activity, near work, screen use, sleep, and diet will be collected as potential confounding factors. Existing clinical laboratory results obtained during routine medical care, including blood lipids, fasting blood glucose, fasting insulin, C-peptide, and glycated hemoglobin, may be included in exploratory analyses when available.

The study will not collect additional blood, stool, or other biological samples solely for research purposes and will not increase the frequency or volume of blood collection. If residual blood remaining after routine clinical testing is available and its use is permitted by the ethics approval and informed consent, it may be used for related laboratory measurements without additional blood collection. The absence of existing laboratory results or residual blood will not affect study eligibility.

Statistical analyses will include group comparisons, multivariable linear or logistic regression, and linear mixed-effects models for repeated follow-up measurements. Analyses will adjust for relevant demographic, familial, and lifestyle factors.

03

Conditions studied

  • Obesity
  • Myopia

Keywords

  • Children
  • Adolescents
  • Body Composition
  • Axial Length
  • Body Mass Index
  • Spherical Equivalent Refraction
  • Myopia Progression
  • Prospective Cohort Study
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of approximately 600 children and adolescents aged 6 to 18 years attending the pediatric outpatient clinic of the Fourth Affiliated Hospital of Nanjing Medical University. Potential participants will be identified through the pediatric outpatient system and referrals from outpatient physicians. Approximately 300 participants will be enrolled in the obesity cohort and 300 in the normal-BMI cohort according to WS/T 586-2018. Enrollment requires written informed consent from a legal guardian and assent from the child or adolescent, as applicable.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 6 to 18 years and able to cooperate with anthropometric measurements, ophthalmic examinations, questionnaire assessments, and follow-up visits.
  • For the obesity cohort, meets the definition of obesity in the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018); for the normal-BMI cohort, body mass index is within the normal range.
  • Best-corrected visual acuity of at least 0.8 in both eyes, with no apparent strabismus, opacity of the refractive media, or ocular structural abnormality.
  • The participant and legal guardian understand the study, voluntarily sign the applicable and assent documents, and are expected to comply with study procedures.
  • Able to complete the questionnaires and planned follow-up assessments.

Exclusion criteria

Exclusion Criteria:

  • An ocular disease that may affect visual acuity or measurement of refractive status, including cataract, glaucoma, fundus disease, apparent strabismus, or another ocular structural abnormality.
  • A severe systemic disease or neurodevelopmental disorder that prevents cooperation with study examinations or follow-up.
  • A secondary condition or factor that substantially affects growth, development, or assessment of body weight.
  • Recent receipt of a myopia-control intervention that may substantially affect the evaluation of myopia progression when complete information about the intervention cannot be obtained.
  • Poor anticipated adherence, inability to complete follow-up, or withdrawal of by the legal guardian.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Obesity Cohort

    Approximately 300 children and adolescents aged 6 to 18 years whose body mass index meets the definition of obesity in the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018). Participants will undergo observational assessments only and will not be assigned to a study intervention.

    Other: Health Education

  • Normal-BMI Cohort

    Approximately 300 children and adolescents aged 6 to 18 years whose body mass index is within the normal range according to the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018). Participants will undergo observational assessments only and will not be assigned to a study intervention.

Interventions

  • OtherHealth Education

    The program should emphasize the health consequences of obesity and evidence-based weight management strategies, including maintaining a balanced diet, controlling energy intake, increasing physical activity, reducing sedentary behavior and screen time, and ensuring adequate sleep. Instruction, individualized counseling, and family involvement should be incorporated to improve health awareness and self-management skills and facilitate the development of a healthy lifestyle.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Axial Length

    Axial length will be measured in millimeters for each eye using the same non-contact optical biometer at baseline and follow-up. Change in axial length (ΔAL) will be calculated as the value at 24 months minus the baseline value. Positive values indicate axial elongation. Changes will be compared between children and adolescents with obesity and those with normal weight. Associations of BMI, BMI-for-age Z score, body fat percentage, and visceral fat level with ΔAL will also be evaluated.

    Time frame: Baseline and 24 months

  2. Change From Baseline in Spherical Equivalent Refractive Error

    Spherical equivalent refractive error will be calculated for each eye as spherical power plus one-half of cylindrical power and expressed in diopters (D), based on cycloplegic autorefraction. Change in spherical equivalent refractive error (ΔSE) will be calculated as the value at 24 months minus the baseline value. A negative change indicates a myopic shift. Changes will be compared between children and adolescents with obesity and those with normal weight. Associations of BMI, BMI-for-age Z score, body fat percentage, and visceral fat level with ΔSE will also be evaluated.

    Time frame: Baseline and 24 months

Secondary outcomes

  1. Change From Baseline in Scleral Thickness

    Scleral thickness will be measured in micrometers at the same predefined anatomical location using optical coherence tomography at baseline and follow-up. Change in scleral thickness (ΔST) will be calculated as the value at 24 months minus the baseline value. A negative change indicates scleral thinning. Changes will be compared between children and adolescents with obesity and those with normal weight.

    Time frame: Baseline and 24 months

  2. Change From Baseline in Regional Choroidal Thickness at 24 Months

    Intraocular pressure, corneal curvature radius, mean keratometry, central corneal thickness, and anterior chamber depth will be measured in both eyes using the same standardized ophthalmic instruments at baseline and at the 24-month follow-up. Changes will be calculated as the 24-month value minus the corresponding baseline value. Intraocular pressure will be expressed in mmHg, corneal curvature radius and anterior chamber depth in millimeters, mean keratometry in diopters, and central corneal thickness in micrometers. Each parameter will be analyzed and reported separately.

    Time frame: Baseline and 24 months

  3. Change From Baseline in Regional Retinal Thickness at 24 Months

    Retinal thickness will be measured in micrometers at predefined temporal, central foveal, and nasal locations in both eyes using optical coherence tomography. Change at each location will be calculated as the value at 24 months minus the corresponding baseline value. Measurements from the temporal, central foveal, and nasal locations will be analyzed and reported separately.

    Time frame: Baseline and 24 months

  4. Change From Baseline in Fasting Lipid Profile at 24 Months

    Fasting lipid profile will include total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, all expressed in mmol/L. Laboratory results obtained during routine clinical care will be collected at baseline and at 24 months when available. Change in each lipid parameter will be calculated as the 24-month value minus the corresponding baseline value. Each lipid parameter will be analyzed and reported separately. No additional blood sampling will be performed solely for this study.

    Time frame: Baseline and 24 months

  5. Body Fat Percentage

    Body fat percentage will be estimated using bioelectrical impedance analysis and expressed as a percentage of total body mass.

    Time frame: Baseline and 24 months

  6. Body Fat Mass

    Fat mass will be estimated using bioelectrical impedance analysis and expressed in kilograms (kg).

    Time frame: Baseline and 24 months

  7. Body Muscle Mass

    Muscle mass will be estimated using bioelectrical impedance analysis and expressed in kilograms (kg).

    Time frame: Baseline and 24 months

  8. Total Body Water

    Total body water will be estimated using bioelectrical impedance analysis and expressed in liters (L).

    Time frame: Baseline and 24 months

  9. Change From Baseline in Fasting Plasma Glucose at 24 Months

    Change in fasting plasma glucose will be calculated as the 24-month value minus the baseline value and expressed in mmol/L.

    Time frame: Baseline and 24 months

  10. Change From Baseline in Fasting Insulin at 24 Months

    Change in fasting insulin will be calculated as the 24-month value minus the baseline value and expressed in µIU/mL.

    Time frame: Baseline and 24 months

  11. Change From Baseline in C-Peptide at 24 Months

    Change in C-peptide concentration will be calculated as the 24-month value minus the baseline value and expressed in pmol/L.

    Time frame: Baseline and 24 months

  12. Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Months

    Change in hemoglobin A1c (HbA1c) will be calculated by subtracting the baseline HbA1c percentage from the 24-month HbA1c percentage. The change will be expressed in percentage points.

    Time frame: Baseline and 24 months

  13. Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at 24 Months

    At each visit, HOMA-IR will be calculated as fasting plasma glucose (mmol/L) multiplied by fasting insulin (µIU/mL), divided by 22.5, when both measurements are available from the same visit. Change will be calculated as the 24-month HOMA-IR value minus the baseline HOMA-IR value. HOMA-IR is a unitless index.

    Time frame: Baseline and 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Masruroh B. The impact of outdoor time on myopia development in overweight children: insights and future research directions. J Public Health (Oxf). 2024 Aug 25;46(3):e565. doi: 10.1093/pubmed/fdae094. No abstract available. PubMed 38857598 ↗
  • Yin C, Gan Q, Xu P, Yang T, Xu J, Cao W, Wang H, Pan H, Luo R, Xiao H, Wang K, Zhang Q. Weight Status and Myopia in Children and Adolescents: A Nationwide Cross-Sectional Study of China. Nutrients. 2025 Jan 12;17(2):260. doi: 10.3390/nu17020260. PubMed 39861390 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 795 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 24 months is below that.

Counting every sponsor, half of 841 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 20, 2026
StartActual
Jul 5, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951528
Responsible party
Weina Liu (Professor, Southeast University, China) — Principal investigator
First posted
Nov 20, 2026
Start date
Jul 5, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Weina Liu, PHD
Contact
weinaliu@seu.edu.cn
+86 18751951966

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion